

INCOME STATEMENT
Three months ended 31st March 2007

	Q1 2007	Q1 2006	Growth	
	£m	£m	CER%	£%
Turnover:				
Pharmaceuticals	4,806	5,045	3	(5)
Consumer Healthcare	786	768	9	2
TURNOVER	5,592	5,813	4	(4)
Cost of sales	(1,234)	(1,134)	14	9
Gross profit	4,358	4,679	2	(7)
Selling, general and administration	(1,673)	(1,823)	(1)	(8)
Research and development	(726)	(753)	2	(4)
Other operating income	207	71		
Operating profit:				
Pharmaceuticals	2,028	2,034	11	-
Consumer Healthcare	138	140	6	(1)
OPERATING PROFIT	2,166	2,174	11	-
Finance income	58	73		
Finance expense	(96)	(92)		
Share of after tax profits of associates and joint ventures	15	15		
PROFIT BEFORE TAXATION	2,143	2,170	10	(1)
Taxation	(610)	(640)	(6)	5
<i>Tax rate %</i>	28.5%	29.5%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,533	1,530	11	-
Profit attributable to minority interests	19	28		
Profit attributable to shareholders	1,514	1,502		
	1,533	1,530		
EARNINGS PER SHARE	27.0p	26.5p	14	2
Diluted earnings per share	26.7p	26.3p		

PHARMACEUTICAL TURNOVER
Three months ended 31st March 2007

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,224	1	(6)	582	(3)	(13)	432	3	2	210	10	(2)
<i>Seretide/Advair</i>	835	11	2	459	12	-	294	8	7	82	14	3
<i>Flixotide/Flovent</i>	155	(4)	(13)	71	(8)	(17)	42	(9)	(11)	42	7	(7)
<i>Serevent</i>	65	(5)	(12)	19	(9)	(17)	32	(8)	(11)	14	7	(7)
<i>Flixonase/Flonase</i>	63	(49)	(52)	25	(72)	(73)	13	-	-	25	17	4
CENTRAL NERVOUS SYSTEM	796	(2)	(11)	565	1	(9)	128	(21)	(22)	103	6	(6)
<i>Seraxat/Paxil</i>	134	(9)	(17)	37	(23)	(30)	34	(17)	(17)	63	7	(6)
<i>Paxil IR</i>	93	(8)	(15)	-	-	-	34	(17)	(17)	59	6	(6)
<i>Paxil CR</i>	41	(10)	(20)	37	(13)	(21)	-	-	-	4	25	-
<i>Wellbutrin</i>	132	(33)	(39)	128	(33)	(40)	1	-	-	3	-	-
<i>Wellbutrin IR, SR</i>	23	-	(4)	20	-	(5)	1	-	-	2	-	-
<i>Wellbutrin XL</i>	109	(37)	(44)	108	(37)	(44)	-	-	-	1	-	-
<i>Imigran/Imitrex</i>	166	1	(9)	136	13	1	21	(41)	(43)	9	-	(10)
<i>Lamictal</i>	250	17	5	200	29	15	35	(25)	(27)	15	13	-
<i>Requip</i>	80	50	38	56	70	51	21	11	11	3	50	50
ANTI-VIRALS	768	20	10	385	28	14	226	11	8	157	15	3
HIV	359	(3)	(10)	164	1	(10)	152	(5)	(7)	43	(7)	(20)
<i>Combivir</i>	115	(13)	(20)	50	(10)	(19)	49	(15)	(17)	16	(14)	(27)
<i>Trizivir</i>	62	(7)	(14)	32	(3)	(14)	27	(16)	(16)	3	33	-
<i>Epivir</i>	41	(27)	(32)	14	(25)	(30)	18	(31)	(31)	9	(21)	(36)
<i>Ziagen</i>	26	(9)	(19)	11	(8)	(15)	9	(9)	(18)	6	(13)	(25)
<i>Agenerase, Lexiva</i>	35	15	6	20	21	5	13	8	8	2	-	-
<i>Epzicom/Kivexa</i>	75	57	47	35	34	21	33	79	74	7	>100	>100
Herpes	250	17	6	166	28	14	36	3	-	48	(4)	(13)
<i>Valtrex</i>	224	22	10	164	29	15	28	12	8	32	-	(9)
<i>Zovirax</i>	26	(13)	(19)	2	-	-	8	(20)	(20)	16	(10)	(20)
<i>Zeffix</i>	40	16	5	3	-	-	6	20	20	31	17	3
<i>Relenza</i>	92	>100	>100	44	>100	>100	32	>100	>100	16	>100	>100
METABOLIC	476	21	10	317	20	7	71	24	22	88	21	9
<i>Avandia products</i>	414	19	8	294	17	5	57	12	12	63	37	21
<i>Avandia</i>	315	1	(8)	232	(2)	(12)	31	(3)	(3)	52	23	11
<i>Avandamet</i>	83	>100	>100	47	>100	>100	26	37	37	10	>100	100
<i>Avandaryl</i>	16	50	33	15	33	25	-	-	-	1	-	-
<i>Bonviva/Boniva</i>	32	>100	>100	23	86	64	9	>100	>100	-	-	-
VACCINES	368	6	1	82	11	(1)	172	6	4	114	3	(3)
<i>Hepatitis</i>	113	4	(3)	32	-	(14)	56	2	2	25	17	4
<i>Influenza</i>	1	-	-	-	-	-	-	-	-	1	-	-
<i>Infanrix/Pediarix</i>	134	15	8	43	17	5	73	10	7	18	27	20
<i>Boostrix</i>	13	40	30	7	60	40	4	33	33	2	-	-
<i>Rotarix</i>	14	>100	100	-	-	-	4	-	-	10	57	43
CARDIOVASCULAR AND	439	13	3	303	15	3	100	6	4	36	11	-
<i>Coreg</i>	217	8	(4)	215	7	(4)	-	-	-	2	100	100
<i>Coreg CR</i>	14	-	-	14	-	-	-	-	-	-	-	-
<i>Coreg IR</i>	203	1	(10)	201	-	(10)	-	-	-	2	100	100
<i>Levitra</i>	14	36	27	13	50	30	-	-	-	1	-	-
<i>Avodart</i>	63	47	34	41	64	46	18	13	13	4	67	33
<i>Arixtra</i>	20	100	82	11	71	57	9	>100	>100	-	-	-
<i>Fraxiparine</i>	47	(6)	(8)	-	-	-	42	(2)	(5)	5	(29)	(29)
<i>Vesicare</i>	11	71	57	11	71	57	-	-	-	-	-	-
ANTI-BACTERIALS	348	(3)	(8)	53	(6)	(15)	175	(1)	(3)	120	(3)	(12)
<i>Augmentin</i>	147	(9)	(14)	24	(13)	(23)	73	(10)	(12)	50	(5)	(11)
ONCOLOGY AND EMESIS	147	(45)	(49)	100	(52)	(56)	32	(20)	(22)	15	(27)	(32)
<i>Zofran</i>	87	(60)	(62)	56	(67)	(69)	20	(33)	(33)	11	(37)	(42)
<i>Hycamtin</i>	30	14	3	19	10	(5)	9	29	29	2	-	-
<i>Tykerb</i>	4	-	-	3	-	-	1	-	-	-	-	-
OTHER	240	5	(4)	32	44	28	56	(3)	(3)	152	2	(8)
<i>Zantac</i>	48	(18)	(26)	16	(14)	(24)	10	(29)	(29)	22	(17)	(27)
	4,806	3	(5)	2,419	3	(7)	1,392	1	-	995	7	(4)

Pharmaceutical turnover includes co-promotion income.

CONSUMER HEALTHCARE TURNOVER
Three months ended 31st March 2007

	Q1 2007 £m	Growth	
		CER%	£%
Over-the-counter medicines	375	8	-
Analgesics	97	11	2
Dermatological	40	8	-
Gastrointestinal	66	11	2
Respiratory tract	56	46	37
Smoking control	78	(10)	(16)
Natural wellness support	30	(3)	(12)
Oral care	248	9	2
Nutritional healthcare	163	12	7
Total	786	9	2